TY - JOUR
T1 - The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders
AU - Costales, Jesse
AU - Kolevzon, Alexander
N1 - Funding Information:
This work was supported by grants from the Beatrice and Samuel A. Seaver Foundation, the Autism Science Foundation, the National Institute of Mental Health (MH100276-01 to AK), and the National Institute of Neurological Disorders and Stroke (U54 NS092090-01 to AK). We would also like to thank the many families that work with us to understand neurodevelopmental disability.
Publisher Copyright:
© 2016 Elsevier Ltd.
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Central nervous system (CNS) development is a finely tuned process that relies on multiple factors and intricate pathways to ensure proper neuronal differentiation, maturation, and connectivity. Disruption of this process can cause significant impairments in CNS functioning and lead to debilitating disorders that impact motor and language skills, behavior, and cognitive functioning. Recent studies focused on understanding the underlying cellular mechanisms of neurodevelopmental disorders have identified a crucial role for insulin-like growth factor-1 (IGF-1) in normal CNS development. Work in model systems has demonstrated rescue of pathophysiological and behavioral abnormalities when IGF-1 is administered, and several clinical studies have shown promise of efficacy in disorders of the CNS, including autism spectrum disorder (ASD). In this review, we explore the molecular pathways and downstream effects of IGF-1 and summarize the results of completed and ongoing pre-clinical and clinical trials using IGF-1 as a pharmacologic intervention in various CNS disorders. This aim of this review is to provide evidence for the potential of IGF-1 as a treatment for neurodevelopmental disorders and ASD.
AB - Central nervous system (CNS) development is a finely tuned process that relies on multiple factors and intricate pathways to ensure proper neuronal differentiation, maturation, and connectivity. Disruption of this process can cause significant impairments in CNS functioning and lead to debilitating disorders that impact motor and language skills, behavior, and cognitive functioning. Recent studies focused on understanding the underlying cellular mechanisms of neurodevelopmental disorders have identified a crucial role for insulin-like growth factor-1 (IGF-1) in normal CNS development. Work in model systems has demonstrated rescue of pathophysiological and behavioral abnormalities when IGF-1 is administered, and several clinical studies have shown promise of efficacy in disorders of the CNS, including autism spectrum disorder (ASD). In this review, we explore the molecular pathways and downstream effects of IGF-1 and summarize the results of completed and ongoing pre-clinical and clinical trials using IGF-1 as a pharmacologic intervention in various CNS disorders. This aim of this review is to provide evidence for the potential of IGF-1 as a treatment for neurodevelopmental disorders and ASD.
KW - ASD
KW - Autism spectrum disorder
KW - CNS development
KW - Central nervous system disorders
KW - Fragile X syndrome
KW - IGF-1
KW - Insulin-like growth factor 1
KW - Neurodevelopmental disorders
KW - Neurotrophic factors
KW - Phelan-McDermid syndrome
KW - Rett syndrome
UR - http://www.scopus.com/inward/record.url?scp=84959189375&partnerID=8YFLogxK
U2 - 10.1016/j.neubiorev.2016.01.001
DO - 10.1016/j.neubiorev.2016.01.001
M3 - Review article
C2 - 26780584
AN - SCOPUS:84959189375
SN - 0149-7634
VL - 63
SP - 207
EP - 222
JO - Neuroscience and Biobehavioral Reviews
JF - Neuroscience and Biobehavioral Reviews
ER -